-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Initiates Coverage On C4 Therapeutics with Buy Rating

Benzinga·12/02/2025 12:20:42
Listen to the news
TD Cowen analyst Tyler Van Buren initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating.